- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 5 of 9.
EudraCT Number: 2008-003016-35 | Sponsor Protocol Number: CLBH589E2214 | Start Date*: 2008-10-07 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: Estudio Fase II de Panobinostat oral, en pacientes adultos con Linfoma de Hodgkin clásico refractario/en recaida, después de fallo a dosis altas de quimioterapia con transfusión autóloga de células... | |||||||||||||
Medical condition: Linfoma de Hodgkin clásico refractario/en recaída | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004130-25 | Sponsor Protocol Number: DUR001-304 | Start Date*: 2016-03-07 |
Sponsor Name:Durata Therapeutic International B.V. | ||
Full Title: A phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteom... | ||
Medical condition: Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive Organisms | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005720-15 | Sponsor Protocol Number: CLZC696A2224 | Start Date*: 2013-09-11 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A randomized, double-blind, active-controlled, parallel group, 52-week study to evaluate the effect of LCZ696 compared to olmesartan on regional aortic stiffness in subjects with essential hyperten... | ||||||||||||||||||
Medical condition: Hypertensive patients. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002204-33 | Sponsor Protocol Number: C32322 | Start Date*: 2007-03-02 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose... | |||||||||||||
Medical condition: Relapsing forms of multiple slerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002721-99 | Sponsor Protocol Number: CT114-2022-01 | Start Date*: 2023-03-28 | |||||||||||
Sponsor Name:Klinikum Nürnberg | |||||||||||||
Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou... | |||||||||||||
Medical condition: Stage 3 chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005057-87 | Sponsor Protocol Number: 337HNAS21016 | Start Date*: 2022-06-15 | |||||||||||
Sponsor Name:Inventiva S.A. | |||||||||||||
Full Title: A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin... | |||||||||||||
Medical condition: Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000203-82 | Sponsor Protocol Number: SHP626-201 | Start Date*: 2016-11-09 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter... | |||||||||||||
Medical condition: Nonalcoholic steatohepatitis (NASH), is a clinical condition occurring in individuals who do not drink excessive alcohol (>20 grams/day), yet have hepatic histology which is indistinguishable from ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002824-42 | Sponsor Protocol Number: SPIRI-201 | Start Date*: 2012-04-17 | |||||||||||
Sponsor Name:Stealth Peptides Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia™ (MTP-131) on Reperfusion Injury in Patients Treated with St... | |||||||||||||
Medical condition: Reperfusion injury in ST-segment Elevation Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002538-14 | Sponsor Protocol Number: 218672 | Start Date*: 2023-06-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: 17-beta-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004709-24 | Sponsor Protocol Number: CERL080ANL05 | Start Date*: 2007-03-20 | |||||||||||
Sponsor Name:ErasmusMC | |||||||||||||
Full Title: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study. | |||||||||||||
Medical condition: Uveitis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011516-37 | Sponsor Protocol Number: 14022009 | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Danish Multiple Sclerosis Research Centre | |||||||||||||
Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl... | |||||||||||||
Medical condition: Multiple Sclerosis, with primary and secondary progressive courses. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002628-34 | Sponsor Protocol Number: thorp8617-1 | Start Date*: 2012-08-29 | |||||||||||
Sponsor Name:Thor Petersen | |||||||||||||
Full Title: Optic neuritis and early treatment with methylprednisolone. | |||||||||||||
Medical condition: Optic neuritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001683-37 | Sponsor Protocol Number: 2018012805 | Start Date*: 2018-07-03 |
Sponsor Name:Rigshospitalet | ||
Full Title: The RIME-IVF study Investigation of RIsk factors in out-of-hospital-cardiac-arrest patients, and MEdical treatment in Idiopathic Ventricular Fibrillation patients | ||
Medical condition: Unexplained cardiac arrest patients after thorough investigations (Idiopathic ventricular fibrillation, IVF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003522-25 | Sponsor Protocol Number: APHP180672 | Start Date*: 2020-02-28 |
Sponsor Name:AP-HP | ||
Full Title: | ||
Medical condition: acute osteomyelitis of the child | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001494-23 | Sponsor Protocol Number: RI-B-2021-7300-07 | Start Date*: 2021-06-10 |
Sponsor Name:Groupe Hospitalier Diaconesses-Croix-Saint-Simon | ||
Full Title: EFFICACY OF ROUTINE MANAGEMENT BY LOCAL ANAESTHETIC INFILTRATION IN THE TREATMENT OF PUDENDAL NEURALGIA: A RANDOMISED TRIAL AGAINST SALINE | ||
Medical condition: Patients with pudendal neuralgia who have failed drug treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000828-19 | Sponsor Protocol Number: NN9535-4662 | Start Date*: 2021-01-25 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease | ||||||||||||||||||
Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) FR (Completed) IT (Completed) ES (Ongoing) DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003755-21 | Sponsor Protocol Number: ISIS304801-CS7 | Start Date*: 2016-06-06 | ||||||||||||||||
Sponsor Name:Akcea Therapeutics | ||||||||||||||||||
Full Title: An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) NL (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000632-26 | Sponsor Protocol Number: TMC-BIV-11-02 | Start Date*: 2013-03-22 | |||||||||||
Sponsor Name:The Medicines Company | |||||||||||||
Full Title: Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 | |||||||||||||
Medical condition: Patients undergoing transcatheter aortic valve replacement (TAVR) procedures performed via the transfemoral approach. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000493-35 | Sponsor Protocol Number: ISIS-304801-CS17 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:Akcea Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy | |||||||||||||
Medical condition: Partial lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001048-40 | Sponsor Protocol Number: B1371013 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib. | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
